HRT and Dementia Risk: What Large Studies Show and Why Timing Matters

A reader wrote to us in January with two screenshots side by side. One headline said hormone therapy had been linked to a 24 percent higher dementia rate. The other said the US drug regulator was removing its long-standing boxed warning about dementia from menopausal hormone products. “Which one do I believe?” she asked. Both are real, and as of early 2026 that collision is exactly why searches for hrt and dementia have surged.

The short version is that the question has been argued over for more than twenty years, and the answer depends heavily on one variable most headlines skip: when a woman started. A 68-year-old beginning hormone therapy for the first time and a 51-year-old starting it for hot flashes are, biologically, in different situations.

This explainer walks through the big trials, the registry studies that worry people, the follow-up data that reassures, and where the evidence is genuinely thin. Where a decision is personal, it belongs with the clinician who knows your history.

Why hrt and dementia is trending again

Hormone replacement therapy (HRT), also called menopausal hormone therapy, means taking estrogen, usually with a progestogen if a woman still has a uterus, to treat menopause symptoms such as hot flashes, night sweats and vaginal dryness. Dementia is an umbrella term for a decline in memory and thinking severe enough to interfere with daily life; Alzheimer’s disease is its most common form.

The two words have been chained together since 2003, when the Women’s Health Initiative Memory Study (WHIMS) reported that older women taking a combined hormone product developed probable dementia at about twice the rate of women on placebo. That single finding reshaped prescribing for a generation.

Three newer events pulled the topic back into the spotlight. In 2023 a Danish registry study of more than 60,000 women found higher dementia rates even among women who began hormone therapy around the usual age of menopause. In 2024 the long-awaited follow-up of a randomized trial in younger women found no cognitive difference roughly a decade after treatment ended. Then, in late 2025, the US Food and Drug Administration announced it would remove the boxed warnings about cardiovascular disease, breast cancer and probable dementia from systemic menopausal hormone products, stating that the original warnings were drawn mainly from women well past menopause.

Put those three together and you get whiplash. A frightening observational result, a reassuring trial result and a regulatory shift arrived within thirty months of each other. None of them cancels the others out. Each answers a slightly different question, which is why the rest of this piece is organized around who was studied, how, and at what age.

What changed recently in the HRT and dementia debate

Here is the dated sequence that explains the current conversation.

May 2003. WHIMS, an ancillary study of the Women’s Health Initiative, published results in 4,532 women aged 65 to 79 randomized to conjugated equine estrogens plus medroxyprogesterone acetate or placebo. The hazard ratio for probable dementia was 2.05, meaning roughly double the rate in the treated group. That paper remains the anchor citation for the dementia warning that later appeared on product labels.

June 2023. Danish researchers published a nationwide case-control study in the BMJ comparing 5,589 women with dementia against 55,890 matched controls. Women who had ever used combined estrogen-progestin therapy had a 24 percent higher dementia rate, and the association held in women who started at age 55 or younger. The authors and the accompanying editorial both stressed that the design could not separate cause from correlation.

November 2024. The Kronos Early Estrogen Prevention Study (KEEPS) Continuation reported in PLOS Medicine. About 275 women who had been randomized in their late 40s and 50s to four years of oral or skin-patch estrogen, or placebo, were retested roughly ten years after stopping. Cognitive scores did not differ between groups.

November 2025. The FDA announced plans to remove the class-wide boxed warning from systemic hormone products for menopause, citing the age profile of the original trial participants. Warnings about endometrial cancer with unopposed estrogen were to remain.

What has not changed matters just as much. The NHS, Mayo Clinic and Cleveland Clinic patient guidance all continue to say the same thing: hormone therapy is prescribed to treat menopause symptoms and, in some women, to protect bone, not to prevent dementia or heart disease. The label change alters how risk is communicated; it does not create new evidence of brain benefit.

What the evidence actually says, graded by strength

Medical evidence comes in tiers. A randomized controlled trial assigns treatment by chance, so differences between groups can be attributed to the treatment. An observational study watches what people chose to do, which is cheaper and larger but vulnerable to confounding: the possibility that the women who took hormones differed in ways that independently affected their risk. Expert opinion sits at the bottom, useful for filling gaps but not for settling arguments.

Randomized trial evidence (strongest). One large trial, WHIMS, shows harm with a specific combined oral product started at 65 or older. Its estrogen-only arm in 2,947 women with a prior hysterectomy showed a hazard ratio of 1.49 that did not reach statistical significance. Smaller trials in younger women, including KEEPS and the Early versus Late Intervention Trial with Estradiol (ELITE), found neither benefit nor harm on cognition. No randomized trial has shown that hormone therapy prevents dementia at any age.

Observational evidence (moderate, conflicting). Finnish and Danish national registries report higher dementia rates with hormone use, including long-term use. Some US insurance-claims analyses report lower rates, particularly with estrogen-only therapy or longer duration. When good studies point in opposite directions, the honest reading is that confounding is doing a lot of work on at least one side.

Expert consensus. Menopause societies and national health services agree on two points: hormone therapy should not be started to protect the brain, and there is no convincing evidence of cognitive harm when it is started under age 60 or within ten years of the final period to treat symptoms.

The grading leads to an uncomfortable but accurate summary. The strongest evidence of harm applies to women most unlike the typical new user today. The reassuring trial evidence in younger women is solid but small. Everything in between is observational and disputed.

Why the Women's Health Initiative Memory Study alarmed everyone

Numbers tell the WHIMS story better than adjectives. Among women on combined therapy, probable dementia occurred at 45 cases per 10,000 person-years, compared with 22 per 10,000 on placebo. In plain terms, for every 10,000 women treated for a year, about 23 additional women received a dementia diagnosis. The trial was stopped early, and the finding was consistent across the subgroups researchers checked.

Three features of the study population deserve attention before anyone applies the result to themselves.

First, age. Every participant was 65 or older, and the average was about 71. Most were at least a decade past menopause. Second, vascular health. Many had high blood pressure, high cholesterol or a history of smoking, conditions that damage small brain blood vessels over time. Third, the product. The trial used one oral formulation combining horse-derived estrogens with a synthetic progestin, taken daily. It did not test skin patches, body-identical estradiol or micronized progesterone, which are now common.

Researchers also noticed that the excess cases skewed toward women with lower baseline cognitive scores, which raised a hypothesis that hormones might accelerate decline already under way rather than start it. Brain imaging in a subset showed slightly smaller frontal lobe and hippocampal volumes in treated women. The hippocampus is the seahorse-shaped structure deep in the brain that is essential for forming new memories.

WHIMS was and remains a well-run randomized trial. Its result is real for the women it studied. The mistake, repeated for years, was reading it as a verdict on all hormone therapy for all women at all ages. A finding in 71-year-olds does not automatically transfer to a 52-year-old with night sweats, any more than a drug’s effect in children transfers to adults.

Does HRT cause dementia? Reading the 2023 Danish study carefully

The Danish study is the one most often quoted in viral posts, so it deserves a careful look rather than a dismissal.

Researchers used national registries covering every Danish woman aged 50 to 60 in the year 2000 and followed records through 2018. They identified 5,589 women later diagnosed with dementia and matched each to ten controls of the same age without dementia. Women who had ever filled prescriptions for combined estrogen-progestin therapy had a hazard ratio of 1.24 for dementia. The association was present whether progestin was given cyclically or continuously, rose with duration of use, and was still visible in women who began treatment at or before age 55.

That last point is why the study unsettled people. It appeared to challenge the idea that starting early is protective. Two cautions keep it in proportion.

Confounding by indication is the first. Women prescribed hormone therapy tend to be those with the most severe hot flashes and the most disrupted sleep. Severe vasomotor symptoms have themselves been linked in observational work to cardiovascular risk markers and to later cognitive complaints. If the symptom, not the treatment, drives part of the risk, a study like this cannot tell the difference.

Detection is the second. Women taking prescribed hormones see clinicians more often. More contact means more chances for memory concerns to be noticed and coded, which inflates recorded diagnoses in the treated group regardless of true incidence.

The BMJ editorial that accompanied the paper concluded that the findings could not establish causation and should prompt further research rather than changes in practice. That remains the mainstream reading. The study does not prove that HRT causes dementia; it shows an association that deserves explanation.

The HRT timing hypothesis: is there a window for the brain?

The timing hypothesis proposes that estrogen supports brain and blood-vessel health when it is given to tissues that are still healthy, and may do nothing or even harm once vessels are already damaged by years of hormone loss and ageing. It grew out of two observations: WHIMS found harm in older women, while younger women in trials did not show it.

Biology offers a plausible story. Estrogen receptors are concentrated in the hippocampus and prefrontal cortex. Estrogen increases glucose uptake by brain cells, supports connections between neurons and relaxes blood-vessel walls. In laboratory studies, those effects appear in healthy neurons but weaken or reverse in neurons already stressed by injury, a pattern sometimes called the healthy-cell bias.

Human evidence partly supports the idea and partly undercuts it. ELITE, a randomized trial published in 2016, found that estradiol slowed thickening of the carotid artery wall in women within six years of menopause but not in women more than ten years past it, a neat fit with the hypothesis. The same trial, though, found no difference in cognition in either age group. KEEPS and its continuation likewise found neither harm nor benefit.

So the timing hypothesis currently explains why starting late may be risky. It does not yet show that starting early protects memory. A 2023 pooled analysis of observational studies suggested lower dementia rates when hormones were begun in midlife and higher rates when begun late, but pooled observational data inherit every confounder of the studies that feed them.

The practical takeaway is modest and well supported: if a woman and her clinician decide hormone therapy is appropriate for symptoms, starting before 60 or within ten years of the final period places her in the group where trials show no cognitive harm. That is reassurance about safety, not a promise of protection.

HRT and dementia risk: the key studies at a glance

Reading the studies side by side makes the pattern easier to see. Notice how age at the start of therapy and study design track with the direction of the result.

Study (year)	Design	Age at start	Size	Main finding on dementia or cognition
WHIMS combined arm (2003)	Randomized trial	65–79	4,532	Probable dementia hazard ratio 2.05; about 23 extra cases per 10,000 women per year
WHIMS estrogen-only arm (2004)	Randomized trial	65–79	2,947	Hazard ratio 1.49, not statistically significant
KEEPS (2015) and Continuation (2024)	Randomized trial, long follow-up	42–58, within 3 years of menopause	727; about 275 at follow-up	No cognitive benefit or harm during treatment or about 10 years later
ELITE (2016)	Randomized trial	Early (under 6 years) vs late (over 10 years) post menopause	643	Slower artery thickening in early group; no cognitive difference in either group
Finnish registry (2019)	Observational case-control	Mostly 50s and 60s	About 84,700 cases	Alzheimer’s rate 9–17 percent higher with systemic use; vaginal estrogen not associated
Danish registry (2023)	Observational case-control	50–60 at baseline	5,589 cases, 55,890 controls	Dementia hazard ratio 1.24 with combined therapy; rose with duration

Two things stand out. Every randomized trial in women under 60 is neutral. Every signal of harm comes either from women over 65 in a trial or from observational registries that cannot rule out confounding. There is no randomized evidence of protection anywhere in the table, and no randomized evidence of harm in younger starters.

A hazard ratio of 1.24 also needs context. If a woman’s baseline lifetime risk of dementia is around one in five, a 24 percent relative increase would move it to roughly one in four, assuming the association were entirely causal, which the study itself could not show.

Estrogen and Alzheimer's risk: does the type of HRT matter?

Hormone therapy is not one thing. Estrogen comes as conjugated equine estrogens or as estradiol, the form the ovaries make. It is taken by mouth, absorbed through a skin patch or gel, or applied vaginally. A progestogen is added for women with a uterus to protect its lining, and that can be a synthetic progestin or micronized progesterone. Each combination has a different fingerprint in the body.

On dementia specifically, the evidence for differences by type is thin and almost entirely observational.

Estrogen-only versus combined. In WHIMS, the estrogen-only arm showed a smaller, non-significant increase compared with the combined arm. The Danish study found its association with combined therapy; several US claims analyses have reported lower dementia rates with estrogen-only use. Whether the progestin component matters, or whether women on estrogen alone simply differ (all have had a hysterectomy), is unresolved.

Oral versus transdermal. Skin-patch estradiol bypasses the liver on first pass and, in observational studies, carries a lower risk of blood clots than oral estrogen. Since small clots and vessel damage are one proposed route to vascular dementia, some researchers expect transdermal therapy to be kinder to the brain. KEEPS randomized women to oral or patch estrogen and found no cognitive difference between either and placebo, so there is no trial proof of a brain advantage.

Vaginal estrogen. Local estrogen for vaginal dryness and urinary symptoms produces very little absorption into the bloodstream. The Finnish registry study found no association between vaginal estrogen and Alzheimer’s disease, and guidance from the NHS and Mayo Clinic treats it as a separate, lower-risk category.

Choosing between these forms is a prescribing decision that weighs clot risk, breast history, symptom pattern and preference. Dementia evidence alone is not strong enough to drive that choice in either direction.

Should a 70-year-old woman take estrogen?

This is one of the most searched questions on the topic, and the guideline answer is clearer than most.

Mayo Clinic, the NHS and major menopause societies advise against starting systemic hormone therapy for the first time after age 60 or more than ten years after the final menstrual period, unless there is a specific, carefully weighed reason. The rationale comes straight from the trial evidence: WHIMS participants were in exactly this age bracket, and the increases in stroke, blood clots and probable dementia were seen there. Observational work on heart disease points the same way, with late starters showing no cardiovascular benefit and some harm.

Starting estrogen at 70 to protect memory is not supported by any trial. That recommendation is as firm as anything in this field.

Continuing is a different question from starting. A woman who began hormone therapy at 50 and is now 70 has been in the early-start group all along. Guidelines do not impose a hard age cut-off for stopping; instead they recommend an annual review of whether symptoms still justify treatment, whether new risk factors have appeared, and whether bone protection remains a goal. Many women step off in their 60s; some continue with their clinician’s agreement.

Vaginal estrogen is the exception that often gets lost. Genitourinary symptoms such as dryness, irritation and recurrent urinary infections tend to worsen with age, and local estrogen is considered appropriate at any age for most women because so little reaches the bloodstream.

If you are 70 and wondering, the right move is a frank conversation about what you are trying to treat. Hot flashes that persist into the 70s, fracture risk, a history of blood clots or breast cancer, and current blood pressure all change the calculation, and only the clinician who can see the whole picture should make it.

Is it safe to stop using HRT after 15 years?

Fifteen years is longer than average, but it is not unusual, and the first thing to say is that there is no evidence that stopping hormone therapy triggers dementia. The worry some readers have, that the brain has become dependent on estrogen and will decline when it is withdrawn, has no support in trial data. KEEPS participants stopped after four years and showed no cognitive drop a decade later.

Stopping does have predictable effects, and knowing them in advance makes the process easier.

Symptoms may return. In studies of women discontinuing after several years, somewhere between a third and half experienced a recurrence of hot flashes or night sweats, usually milder than the original episode and often settling within months. A minority find symptoms return at full strength.

Bone protection ends. Estrogen slows bone loss only while it is being taken. After stopping, the rate of loss returns to what it would have been, so women with low bone density may need a plan for monitoring or alternative protection.

Gradual versus abrupt. Both approaches are used in practice. The limited trials comparing them have not found a clear difference in how often symptoms come back, so the choice is usually about personal preference and how severe symptoms were in the first place. Your prescriber will decide the approach and the pace.

Why women stop after 15 years varies: a new diagnosis, a change in breast or clot risk, a desire to see whether symptoms have faded, or simply the annual review landing differently this time. All are legitimate. What guidance consistently warns against is stopping suddenly on your own in response to a headline. A planned stop, with a follow-up appointment booked, lets you and your clinician judge the result and reconsider if needed.

What are the common side effects of hormone replacement therapy?

Side effects shape whether women continue hormone therapy more than dementia statistics do, so they belong in any honest discussion.

Common, usually mild effects in the first weeks include breast tenderness, bloating, nausea, headaches, leg cramps, mood changes and irregular spotting or bleeding. The NHS notes that most of these settle within about three months as the body adjusts. Breast tenderness and bleeding patterns relate to the progestogen component and often lead clinicians to adjust the type or schedule, a decision for the prescriber.

Less common but more serious risks depend on the form of therapy and the woman’s baseline health.

• Blood clots. Oral estrogen roughly doubles the risk of a clot in the leg or lung in observational studies; transdermal estrogen shows little or no increase.
• Stroke. A small increase was seen in the Women’s Health Initiative, concentrated in women who started after 60.
• Breast cancer. Combined estrogen-progestogen therapy taken for more than about five years is associated with a modest increase that falls after stopping. Estrogen-only therapy shows little or no increase in most studies.
• Endometrial cancer. Estrogen without a progestogen raises the risk in women who still have a uterus, which is why the two are prescribed together.
• Gallbladder disease. More common with oral estrogen.

Set against these are benefits that the same trials documented: substantial relief of hot flashes and night sweats, improved sleep in many women, fewer hip and spine fractures, and relief of vaginal and urinary symptoms.

Every one of these risks is modified by age at starting, duration, route and personal history. A single list cannot tell you which apply to you. The NHS and Mayo Clinic references at the end of this article give the fuller breakdown, and the prescriber who knows your records is the person to weigh them.

Common myths about menopause hormone therapy and dementia

Viral claims about hrt and dementia tend to fall into a handful of recurring shapes. Here is what the evidence says about each.

Myth: “HRT causes Alzheimer’s.” The strongest evidence of increased dementia risk comes from one randomized trial in women aged 65 to 79 taking one combined oral product. Trials in women who started before 60 show no cognitive harm. Registry studies show associations, not causation. “Causes” overstates what any study has demonstrated.

Myth: “HRT prevents dementia if you start early.” Appealing, biologically plausible and unproven. No randomized trial has shown that starting hormones in the 40s or 50s lowers dementia rates. The reassuring trial data show absence of harm, which is not the same as protection.

Myth: “The boxed warning was removed, so the brain question is settled.” The regulatory change reflects a judgment that the old warning, based on older women, overstated risk for typical users. It did not rest on new evidence that hormones protect cognition, and clinical guidance still says not to use them for that purpose.

Myth: “Compounded bioidentical hormones are safer for the brain.” Custom-mixed hormone preparations made by compounding pharmacies are not approved by drug regulators, are not tested for consistency or long-term safety, and have no dementia data at all. They are not a route to brain protection and are not for self-use. Regulator-approved estradiol and micronized progesterone are themselves body-identical and are what trials have tested.

Myth: “If you carry the APOE4 gene, HRT will help (or harm).” APOE4 is a gene variant that raises Alzheimer’s risk. Small observational studies have suggested carriers might respond differently to estrogen, in both directions. The data are too sparse to guide treatment, and no guideline recommends testing for APOE4 to decide on hormone therapy.

What are four drugs linked to increased dementia risk?

Readers who search for hormone therapy and dementia often land on lists of “four drugs that cause dementia.” The lists vary, but four classes come up repeatedly in observational research, and it helps to understand why they appear and what the evidence actually supports.

Anticholinergic medicines. These block acetylcholine, a brain chemical central to memory. The group includes some first-generation antihistamines such as diphenhydramine, older tricyclic antidepressants such as amitriptyline, and several medicines for overactive bladder such as oxybutynin. A 2019 observational study of nearly 285,000 people found that heavy cumulative use over years was associated with roughly a 50 percent higher dementia rate. The association is consistent across studies, but confounding remains possible because early dementia itself can lead to prescriptions for sleep, mood or bladder problems.

Benzodiazepines and related sleep medicines. Drugs such as diazepam, lorazepam and zolpidem are associated in several cohorts with higher dementia rates, though results are inconsistent and the reverse-causation problem is especially strong, since anxiety and insomnia are early dementia symptoms.

Opioid pain medicines. Some studies link long-term use to cognitive decline; others do not. Evidence is weak.

Proton pump inhibitors. Acid-reducing medicines such as omeprazole showed an association in early German studies that larger analyses have mostly not confirmed. Current evidence does not support a causal link.

Two points matter more than the list itself. First, all of this is observational; none of these medicines has been shown in a trial to cause dementia. Second, every one of them is prescribed because it treats something real. Stopping a bladder medicine, antidepressant or sleep aid abruptly can cause harm of its own. If a medicine on this list is part of your routine, the right step is to ask your prescriber or pharmacist for a medication review, not to stop it yourself.

When to see a doctor about HRT, memory or dementia concerns

Most people reading about hormones and memory are not in crisis; they are trying to make a sensible decision. Even so, certain situations call for an appointment rather than more reading.

Book a routine visit if you:

• are taking hormone therapy and have not had a review in the past twelve months
• are considering starting, stopping or switching and want to understand your personal balance of benefits and risks
• are over 60 or more than ten years past menopause and have been offered systemic hormones for the first time
• take several medicines, including any for sleep, bladder, mood or allergies, and want a medication review
• have noticed gradual memory changes that worry you or your family, such as repeating questions, misplacing items in unusual places, or trouble following familiar recipes or routes

Seek urgent medical attention for red-flag signs, which can indicate a blood clot, stroke or another emergency rather than anything to do with dementia:

• sudden weakness, numbness or drooping on one side of the face or body
• sudden confusion, trouble speaking or understanding speech
• sudden severe headache unlike any you have had before
• sudden loss of vision in one or both eyes
• chest pain, breathlessness or coughing up blood
• a painful, swollen, warm or red calf

Call emergency services for any of these; do not wait to see whether they pass.

Also contact your clinician promptly about unexplained vaginal bleeding after menopause, a new breast lump or skin change, or new jaundice (yellowing of the skin or eyes), all of which need assessment while on hormone therapy.

A memory concern evaluation typically involves a conversation, a short cognitive test, blood tests to rule out treatable causes such as thyroid or vitamin B12 problems, and sometimes imaging. Early assessment helps whether or not the answer turns out to be dementia. Every decision about hormone therapy, including whether to continue, pause or change, belongs with the clinician who prescribes it and knows your history.

Frequently asked questions

Does HRT cause dementia?

The evidence does not show that HRT causes dementia in women who start it around the time of menopause. One large randomized trial found roughly double the rate of probable dementia in women who began a combined oral product after age 65. Trials in women under 60 found no cognitive harm. Registry studies show statistical associations that cannot prove cause, partly because women with the most severe symptoms are also the most likely to be prescribed hormones.

Does menopause hormone therapy protect against dementia if started early?

Not according to randomized trials. The timing hypothesis predicts that estrogen started close to menopause supports brain blood vessels, and some observational analyses point that way, but no trial has shown lower dementia rates. KEEPS and ELITE, both in younger women, found no cognitive benefit. The responsible summary is that early use appears safe for cognition, which is reassuring, but it is not a reason to take hormones for brain protection.

What is the HRT timing hypothesis?

The timing hypothesis proposes that estrogen helps blood vessels and brain cells when given to tissue that is still healthy, typically within ten years of menopause, and may be neutral or harmful when started later in vessels already damaged by ageing. Trial data support the harm-when-late half: older starters in WHIMS had more dementia and stroke. The protection-when-early half remains unproven for memory, though early starters show no cognitive harm.

Should a 70-year-old woman start estrogen for memory?

No major guideline supports starting systemic estrogen at 70 to protect memory. The only large randomized trial in that age group found more probable dementia, stroke and blood clots. Continuing therapy that began decades earlier is a separate decision reviewed yearly. Vaginal estrogen for dryness or urinary symptoms is considered appropriate at most ages because little enters the bloodstream. Any decision rests with the clinician who knows the woman’s full history.

Is it safe to stop HRT after 15 years?

Stopping after 15 years is a common and generally safe decision when planned with a clinician. There is no evidence that stopping causes dementia. Hot flashes return in roughly a third to half of women, usually milder than before, and bone loss resumes at the normal postmenopausal rate. Gradual and abrupt approaches show similar results in limited studies. The prescriber decides the method, and a follow-up visit lets you reassess together.

What are the common side effects of hormone replacement therapy?

Common early effects include breast tenderness, bloating, nausea, headaches, mood changes and irregular bleeding, most of which settle within about three months. Less common serious risks include blood clots and stroke, mainly with oral estrogen and in older starters, a modest increase in breast cancer with combined therapy used beyond about five years, and endometrial cancer if estrogen is taken without a progestogen by a woman with a uterus. Your prescriber can weigh these against your symptoms.

What did the Women's Health Initiative find about HRT and dementia?

The Women’s Health Initiative Memory Study randomized 4,532 women aged 65 to 79 to combined estrogen-progestin therapy or placebo and found probable dementia in 45 versus 22 per 10,000 person-years, a hazard ratio of 2.05. The estrogen-only arm showed a smaller, non-significant increase. Because participants were well past menopause and many had vascular risk factors, researchers caution against applying the result to women who start treatment in their 40s or 50s.

Does estrogen affect Alzheimer's risk differently from other types of dementia?

Studies usually report all-cause dementia or Alzheimer’s disease together, so the evidence does not separate them cleanly. Estrogen’s proposed brain effects run through blood vessels and through nerve cells that carry estrogen receptors, so both vascular dementia and Alzheimer’s are biologically plausible targets. WHIMS counted probable dementia of all types. The Finnish registry study focused on Alzheimer’s and found a 9 to 17 percent higher rate with systemic hormones but none with vaginal estrogen.

What are four drugs that increase the risk of dementia?

Observational research most consistently links anticholinergic medicines, such as some first-generation antihistamines, tricyclic antidepressants and bladder antimuscarinics, with higher dementia rates after years of heavy use. Benzodiazepines and related sleep medicines show weaker, inconsistent associations, and evidence for opioids and proton pump inhibitors is weakest. None has been proven to cause dementia in a trial. Do not stop any prescribed medicine on your own; ask for a medication review instead.

Are compounded bioidentical hormones safer for the brain?

There is no evidence that compounded bioidentical hormones are safer for the brain, and there are no dementia studies of them at all. Custom-mixed preparations are not approved by drug regulators, are not tested for consistent strength or long-term safety, and are not intended for self-use. Regulator-approved estradiol and micronized progesterone are themselves identical to the body’s hormones and are the forms that trials such as KEEPS actually studied.

References

• MedlinePlus: Hormone Replacement Therapy
• NHS: Hormone replacement therapy (HRT)
• Cleveland Clinic: Hormone Therapy for Menopause Symptoms

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.